Business
Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results
Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter revenue growth of 19% to $29.5 million2025 revenue growth of 20% to
About this update from Mdxhealth Sa
[{"type":"text","content":"Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter revenue growth of 19% to $29.5 million2025 revenue growth of 20% to $107.9 millionConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the \"Company\" or \"mdxhealth\"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report another year of 20% revenue growth which reflects continued operating discipline and commercial execution by our team. Our consistent growth is a result of our strategy to build an incomparable menu of precision diagnostics for urologists and patients navigating the complex diagnostic pathway of prostate cancer. “Our growth ambitions go well beyond where we have been and where we are today, which informs our confidence in sustainable growth going forward. We expect our business to accelerate in 2026, reflected in our 2026 guidance of $137-140 million representing 27-30% growth. We also expect to drive improved productivity and operating leverage, leading to a 10% adjusted EBITDA margin exiting 2026.” Key Highlights: 2025 revenue of $107.9 million, an increase of 20% over 2024Fourth quarter revenue of $29.5 million, an increase of 19% over prior year periodFourth quarter adjusted EBITDA of ($2.1) million, a 53% increase over prior year periodFourth quarter tissue-based (Confirm mdx and GPS) test volume of 11,201, a decrease of 5% over prior year periodFourth quarter liquid-based (ExoDx, Select mdx, Resolve mdx, Germline) test volume of 27,486, an increase of 128% over prior year periodYear-end cash and cash equivalents balance of $29.0 million Financial review for the fourth quarter and year ended December 31, 2025 USD in ‘000 (except per share data)Unaudited Three months ended December 31 Twelve months ended December 31 20252024% Change 20252024% ChangeRevenue 29,54524,73919% 107,87590,04920%Cost of goods (10,858)(9,222)18% (38,242)(34,908)10%Gross Profit 18,68715,51720% 69,63355,14126%Operating expenses (23,949)(20,125)19% (84,041)(79,863)5%Operating loss (5,262)(4,608)14% (14,408)(24,722)(42%)Net loss (8,928)(6,841)31% (33,519)(38,069)(12%)Adjusted EBITDA* (2,112)(1,...